REDX, the Liverpool and Cheshire-based drug discovery and development company, says has identified an exciting potential treatment for hard-to-treat cancers. The drug, if it progresses through human trials, could be an affective alternative treatment to cancer in the pancreas, ‘triple negative’ breast and head and neck cancers.
A statement said: “Redx believes the superior characteristics of the company’s compound could result in a best-in-class drug, making the commercial potential for this new development candidate particularly attractive.”
Chief executive Dr Neil Murray, added: “We’re delighted to be announcing the fourth drug candidate to make it through our development pipeline. Our novel Porcupine inhibitor has the potential to tackle some of the most hard-to-treat cancers and we are particularly excited by the prospects for this target in immuno-oncology.
See the article in full at BusinessDesk.com